Increase of the T-reg-recruiting chemokine CCL22 expression in a progressive course of cervical dysplasia

[1]  Ying Liang,et al.  IL‐6 expression promoted by Poly(I:C) in cervical cancer cells regulates cytokine expression and recruitment of macrophages , 2020, Journal of cellular and molecular medicine.

[2]  U. Jeschke,et al.  Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients , 2019, Cancers.

[3]  Li‐Wha Wu,et al.  Cancer‐associated fibroblast‐derived interleukin‐1β activates protumor C‐C motif chemokine ligand 22 signaling in head and neck cancer , 2019, Cancer science.

[4]  C. Nishiyama,et al.  A transcription factor PU.1 is critical for Ccl22 gene expression in dendritic cells and macrophages , 2019, Scientific Reports.

[5]  U. Jeschke,et al.  PPARγ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas , 2018, International journal of molecular sciences.

[6]  M. Kyrgiou,et al.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis , 2018, British Medical Journal.

[7]  F. Geissmann,et al.  Yolk sac macrophage progenitors traffic to the embryo during defined stages of development , 2018, Nature Communications.

[8]  V. Arolt,et al.  The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity , 2017, International journal of molecular sciences.

[9]  L. Liang,et al.  Clinical Significance of CD163+ and CD68+ Tumor-associated Macrophages in High-risk HPV-related Cervical Cancer , 2017, Journal of Cancer.

[10]  A. Chakravarthy,et al.  The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2 , 2017, Molecular cell.

[11]  Juan Zhao,et al.  Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma , 2017, Virology Journal.

[12]  Jingping Yuan,et al.  Co-evolution of tumor-associated macrophages and tumor neo-vessels during cervical cancer invasion , 2016, Oncology letters.

[13]  Marc Arbyn,et al.  Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis , 2016, British Medical Journal.

[14]  Roberto Romero,et al.  An M1-like Macrophage Polarization in Decidual Tissue during Spontaneous Preterm Labor That Is Attenuated by Rosiglitazone Treatment , 2016, The Journal of Immunology.

[15]  J. Bae,et al.  Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment , 2016, Mediators of inflammation.

[16]  K. Kelsey,et al.  Serum macrophage‐derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time , 2015, International journal of cancer.

[17]  L. Fu,et al.  Tumor Secretion of CCL22 Activates Intratumoral Treg Infiltration and Is Independent Prognostic Predictor of Breast Cancer , 2013, PloS one.

[18]  M. Grabiec,et al.  The Analysis of Metallothionein Immunoreactivity in Stromal Fibroblasts and Macrophages in Cases of Uterine Cervical Carcinoma With Respect to Both the Local and Distant Spread of the Disease , 2013, American journal of reproductive immunology.

[19]  M. lenhard,et al.  The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients , 2013, PloS one.

[20]  M. Weiser-Evans,et al.  Activation of PPARγ in Myeloid Cells Promotes Lung Cancer Progression and Metastasis , 2011, PloS one.

[21]  S. H. van der Burg,et al.  M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells , 2011, The Journal of Immunology.

[22]  G. Pizzolo,et al.  Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12 , 2010, Molecular Cancer.

[23]  P. Arck,et al.  Nuclear Receptors of the Peroxisome Proliferator-Activated Receptor (PPAR) Family in Gestational Diabetes: From Animal Models to Clinical Trials1 , 2010, Biology of reproduction.

[24]  L. Villa,et al.  Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth , 2010, BMC Immunology.

[25]  Isao Usui,et al.  Regulatory Mechanisms for Adipose Tissue M1 and M2 Macrophages in Diet-Induced Obese Mice , 2009, Diabetes.

[26]  W. Prendiville,et al.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.

[27]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[28]  T. Curiel.  Regulatory T cells and treatment of cancer. , 2008, Current opinion in immunology.

[29]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[30]  I. Slukvin,et al.  Dynamic changes in primate endometrial leukocyte populations: differential distribution of macrophages and natural killer cells at the rhesus monkey implantation site and in early pregnancy. , 2004, Placenta.

[31]  H. Bernard,et al.  The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. , 2003, Virology.

[32]  F. X. Bosch,et al.  Environmental co-factors in HPV carcinogenesis. , 2002, Virus research.

[33]  Christoph Schaniel,et al.  Activated Murine B Lymphocytes and Dendritic Cells Produce a Novel CC Chemokine which Acts Selectively on Activated T Cells , 1998, The Journal of experimental medicine.

[34]  C. H. Buckley,et al.  Aetiology, pathogenesis, and pathology of cervical neoplasia. , 1998, Journal of clinical pathology.

[35]  P. Allavena,et al.  Human Macrophage–derived Chemokine (mdc), a Novel Chemoattractant for Monocytes, Monocyte-derived Dendritic Cells, and Natural Killer Cells , 1997 .

[36]  J. Nevins,et al.  Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[37]  B. Melichar,et al.  Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies , 2004, International Journal of Gynecologic Cancer.

[38]  B. Davidson,et al.  Inflammatory Response in Cervicallntraepithelial Neoplasia and Squamous Cell Carcinoma of the Uterine Cervix , 1997 .